Customize your JAMA Network experience by selecting one or more topics from the list below.
Puthumana J, Wallach JD, Ross JS. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation. JAMA. 2018;320(3):301–303. doi:10.1001/jama.2018.7619
The US Food and Drug Administration (FDA) Safety and Innovation Act of 2012 created the Breakthrough Therapy designation to expedite development and review of drugs and biologics intended to treat serious or life-threatening conditions for which preliminary clinical evidence may demonstrate substantial improvement over existing therapies, allowing the FDA to provide “intensive guidance on efficient drug development” and “rolling review.”1 Although physicians and patients often perceive that breakthrough approvals are based on rigorous clinical evidence,2,3 no systematic evaluation of the evidence supporting breakthrough approvals has occurred. We reviewed all new FDA approvals granted Breakthrough Therapy designation, characterizing the pivotal clinical trials that serve as the basis of FDA approval,4 and premarket development and review times.
Create a personal account or sign in to: